Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor Oral Dapansutrile

October 27, 2020) Olatec Therapeutics LLC announced today that it is currently enrolling non-hospitalized COVID-19 patients with the aim to treat and prevent damaging effects of IL-1-induced inflammation that can lead to a fulminant Cytokine Storm. The trial is described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome.” …

The release as fetched from its publisher. olatec.com ↗